Qnexa is an investigational drug, taken orally for the treatment ofobesity. In April this year, Vivus Inc., its manufacturer,submitted its response to the Day 180 List of Outstanding Issues.European Medicines Agency's (EMA) Committee for Medicinal Productsfor Human Use (CHMP) has scheduled an oral hearing in regards tothe drug for September this year, and the CHMP opinion on Qnexa isexpected to be released shortly after the meeting. Peter Tam, president of VIVUS said that : "We appreciate the flexibility of the CHMP to work with us on thetiming of the oral hearing and the scheduling in September ... Welook forward to presenting to the CHMP in September, but arecurrently focused on working with the FDA ahead of the July 17,2012 PDUFA and the potential Qnexa launch in the U.S. in the secondhalf of this year." Meanwhile, in the US, Vivus said it is focusing on working with theUS Food and Drug Administration in the run up to its July 17thmeeting. Vivus said it expects approval of the drug and plans tobegin full marketing of the drug in the later part of 2012. Qnexais one of three obesity drugs pending approval, after the FDA initially rejected them, ongrounds of harmful side effects, such as heart problems. Obesity is seen as being one of the most pressing public healthissues with incidence rising rapidly over the last decade andprojected to accelerate into the future. Obesity causes all mannerof health problems for sufferers, including early onset type two diabetes , cardiovascular problems and general loss of quality of life. Qnexa [kyoo-nek-suh] was developed to address weight loss, type 2diabetes and obstructive sleep apnea . Qnexa is taken once-a-day as a controlled-release formulation oflow-dose phentermine and topiramate. These drugs are designed todecrease appetite and increase satiety (the sense of feeling full),the two main mechanisms that impact eating behavior. In Phase 2 and Phase 3 clinical data to date, patients taking Qnexahave demonstrated statistically significant weight loss, betterglycemic control, and improvement in cardiovascular risk factorswhen they used the drug in combination with a diet and lifestylemodification program. Written by Rupert Shepherd Copyright: Medical News Today Not to be reproduced without permission of Medical News Today Additional References Citations. I am an expert from steelseamlesspipe.com, while we provides the quality product, such as Steel Flanges Manufacturer , Alloy Steel Seamless Tubes Manufacturer, Stainless Steel Seamless Pipe,and more.
Related Articles -
Steel Flanges Manufacturer, Alloy Steel Seamless Tubes Manufacturer,
|